NEU neuren pharmaceuticals limited

Ann: Validation for NNZ-2591 neurodevelopmental disorder pipeline, page-86

  1. 547 Posts.
    lightbulb Created with Sketch. 1345
    I fully agree;
    Acadia was rejected by neuren because her offer was considered too modest. Neuren right now needs a good treasure to progress on the 2591 directions given last Friday and a few million dollars to refinance the options of two executives if the market sets on certain levels. we are in fact at a crucial point that will give us clear indications of how things are.

    the technical signal of today is strong given that it manifests itself too close to that of last Friday. it is particularly evident that the company has something to give to the market in imminent times; by Sunday 26 the deadline for proxies to be presented at the meeting of 28 and expiry of options for two executives on the 29th is a session left in the middle for the market or that of next Monday. anything can happen and the assumptions of a renewed expectation in the very short are indicated by an unusual activity on the market with transactions of a certain weight that have triggered strong volatility which in this precise context are an index of accumulating institutional activity.the next session will give us further answers and clear elements.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$12.96
Change
-0.140(1.07%)
Mkt cap ! $1.612B
Open High Low Value Volume
$13.20 $13.36 $12.82 $4.627M 354.8K

Buyers (Bids)

No. Vol. Price($)
1 7585 $12.96
 

Sellers (Offers)

Price($) Vol. No.
$13.03 3344 2
View Market Depth
Last trade - 16.10pm 16/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.